- page

Scroll to explore

Scroll back top

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further ...

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock n...

Domain Therapeutics to present three posters at AACR 2023 annual meeting

10 February 2023

International Day of Women and Girls in Science: Presenting Dr Nuria Kotecki

6 February 2023

Domain Therapeutics to Participate in Upcoming Investor and Industry Conferences

The entire Domain Therapeutics team wishes you fair winds in 2023

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients...

8 December 2022

Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology expert...

10 November 2022

Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting

19 October 2022

Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumor...